Lilly's CGRP drug succeeds in 'worst kind of migraine'

Lilly's CGRP drug succeeds in 'worst kind of migraine'

Source: 
Biopharma Dive
snippet: 

An experimental pain medication from Eli Lilly significantly outperformed placebo at reducing the number of weekly cluster headache attacks for patients who experience them intermittently, according to data released Tuesday.